Lyell Immunopharma Inc (LYEL)

Nov 15, 2024

Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know - MSN

Nov 15, 2024

Nov 12, 2024

HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat

Nov 12, 2024

Nov 12, 2024

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts - Benzinga

Nov 12, 2024

Nov 09, 2024

Lyell Immunopharma: Q3 Earnings Snapshot - AOL

Nov 09, 2024

Nov 08, 2024

Lyell Immunopharma Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024

Nov 07, 2024

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - GlobeNewswire

Nov 07, 2024

Nov 06, 2024

Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire

Nov 06, 2024

Nov 05, 2024

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire

Nov 05, 2024

Nov 05, 2024

Lyell's Novel CAR T-Cell Therapy Data to Be Unveiled at ASH 2024 Following FDA Fast Track Status | LYEL Stock News - StockTitan

Nov 05, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Reduction in Lyell Immunopharma I - GuruFocus.com

Nov 05, 2024

Nov 03, 2024

Lyell shares down as BofA double downgrades to Sell - MSN

Nov 03, 2024

Nov 03, 2024

Lyell Immunopharma (NASDAQ:LYEL) Downgraded to “Underperform” Rating by Bank of America - Defense World

Nov 03, 2024

Nov 01, 2024

Lyell Immunopharma acquires ImmPACT Bio to boost CAR T-cell therapy - Investing.com India

Nov 01, 2024

Oct 31, 2024

Lyell Immunopharma Completes Acquisition of ImmPACT Bio - The Manila Times

Oct 31, 2024

Oct 31, 2024

B of A Securities Downgrades Lyell Immunopharma (LYEL) - MSN

Oct 31, 2024

Oct 31, 2024

Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Oct 31, 2024

Oct 30, 2024

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy - Benzinga

Oct 30, 2024

Oct 30, 2024

Lyell shares down as BofA double downgrades to Sell By Investing.com - Investing.com South Africa

Oct 30, 2024

Oct 30, 2024

Lyell cut to underperform by BofA, pipeline reorganization cited - MSN

Oct 30, 2024

Oct 30, 2024

Lyell Immunopharma (NASDAQ:LYEL) Lowered to Underperform Rating by Bank of America - MarketBeat

Oct 30, 2024

Oct 28, 2024

HC Wainwright Reiterates Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat

Oct 28, 2024

Oct 28, 2024

Lyell Immunopharma shares maintain neutral rating on acquisition By Investing.com - Investing.com UK

Oct 28, 2024

Oct 27, 2024

Lyell Immunopharma’s Acquistion of ImmPACT Bio USA - Global Legal Chronicle

Oct 27, 2024

Oct 25, 2024

Lyell Will Seek To Improve On Existing CAR-Ts Via Merger With ImmPACT - Citeline News & Insights

Oct 25, 2024

Oct 25, 2024

Lyell Immunopharma stock hits 52-week low at $1.05 By Investing.com - Investing.com Australia

Oct 25, 2024

Oct 25, 2024

Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline - Pharmaceutical Technology

Oct 25, 2024

Oct 25, 2024

Lyell Immunopharma stock hits 52-week low at $1.05 - Investing.com

Oct 25, 2024

Oct 25, 2024

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth (NASDAQ:LYEL) - Seeking Alpha

Oct 25, 2024

Oct 24, 2024

Lyell, in search of a turnaround, to buy cell therapy startup ImmPact - BioPharma Dive

Oct 24, 2024

Oct 24, 2024

Lyell boosts pipeline with ImmPACT acquisition - Investing.com India

Oct 24, 2024

Oct 24, 2024

Lyell Immunopharma to Buy ImmPact; Refocuses Pipeline on T-Cell Cancer Treatments - MarketWatch

Oct 24, 2024

Oct 24, 2024

Lyell Immunopharma to acquire ImmPACT Bio (NASDAQ:LYEL) - Seeking Alpha

Oct 24, 2024

Oct 24, 2024

Lyell boosts pipeline with ImmPACT acquisition By Investing.com - Investing.com South Africa

Oct 24, 2024

Oct 24, 2024

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes - GlobeNewswire

Oct 24, 2024